The University of Southampton
University of Southampton Institutional Repository

cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate

cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate
cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate
We describe the properties of BG505 SOSIP.664 HIV-1 envelope glycoprotein trimers produced under current Good Manufacturing Practice (cGMP) conditions. These proteins are the first of a new generation of native-like trimers that are the basis for many structure-guided immunogen development programs aimed at devising how to induce broadly neutralizing antibodies (bNAbs) to HIV-1 by vaccination. The successful translation of this prototype demonstrates the feasibility of producing similar immunogens on an appropriate scale and of an acceptable quality for Phase I experimental medicine clinical trials. BG505 SOSIP.664 trimers are extensively glycosylated, contain numerous disulfide bonds and require proteolytic cleavage, all properties that pose a substantial challenge to cGMP production. Our strategy involved creating a stable CHO cell line that was adapted to serum-free culture conditions to produce envelope glycoproteins. The trimers were then purified by chromatographic methods using a 2G12 bNAb affinity column and size-exclusion chromatography. The chosen procedures allowed any adventitious viruses to be cleared from the final product to the required extent of >12 log10. The final cGMP production run yielded 3.52 g (peptidic mass) of fully purified trimers (Drug Substance) from a 200 L bioreactor, a notable yield for such a complex glycoprotein. The purified trimers were fully native-like as judged by negative-stain electron microscopy, and were stable over a multi-month period at room temperature or below and for at least 1 week at 50°C. Their antigenicity, disulfide bond patterns, and glycan composition were consistent with trimers produced on a research laboratory scale. The methods reported here should pave the way for the cGMP production of other native-like Env glycoprotein trimers of various designs and genotypes.
0006-3592
885–899
Dey, Antu K.
3cfcd3d8-ef22-4bcb-bb73-b161d608f7ba
Cupo, Albert
aa9f476e-3296-4118-9231-0edc774b8335
Ozorowski, Gabriel
9d448a80-7310-4b30-ba44-ee8b18222a02
Sharma, Vaneet K.
ab574e7b-a90a-4437-97a9-2004f0d45296
Behrens, Anna-Janina
ed584c40-79cb-4de9-bb9c-bd68c71d6a68
Go, Eden P.
4c2cbf69-492e-4e40-bc4d-9c3e979d8dc8
Ketas, Thomas J.
be22ffd5-bef3-46c4-92fe-db4466a2a098
Yasmeen, Anila
2c47f610-f8ab-4b85-b33e-64837c8345cc
Klasse, Per J.
23277bb2-de88-4e9c-9b54-3fb1193e9d9e
Sayeed, Eddy
ffab4c39-c87b-4397-a492-a68a98ff5372
Desaire, Heather
4186ab6e-fe78-4c8b-a4dc-4b8a0a27bdee
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
Wilson, Ian A.
7865d500-d638-4a67-ad6d-fefad0ae83bb
Sanders, Rogier W.
d3b67c2c-c725-42e7-b972-50b30be67c74
Hassell, Thomas
ace806e6-2de6-4e21-86e5-0b903c99d40a
Ward, Andrew
0175d681-1283-4b75-a75f-b98609660b3d
Moore, John P.
3c26226c-c036-48db-bbd1-828a86b29697
Dey, Antu K.
3cfcd3d8-ef22-4bcb-bb73-b161d608f7ba
Cupo, Albert
aa9f476e-3296-4118-9231-0edc774b8335
Ozorowski, Gabriel
9d448a80-7310-4b30-ba44-ee8b18222a02
Sharma, Vaneet K.
ab574e7b-a90a-4437-97a9-2004f0d45296
Behrens, Anna-Janina
ed584c40-79cb-4de9-bb9c-bd68c71d6a68
Go, Eden P.
4c2cbf69-492e-4e40-bc4d-9c3e979d8dc8
Ketas, Thomas J.
be22ffd5-bef3-46c4-92fe-db4466a2a098
Yasmeen, Anila
2c47f610-f8ab-4b85-b33e-64837c8345cc
Klasse, Per J.
23277bb2-de88-4e9c-9b54-3fb1193e9d9e
Sayeed, Eddy
ffab4c39-c87b-4397-a492-a68a98ff5372
Desaire, Heather
4186ab6e-fe78-4c8b-a4dc-4b8a0a27bdee
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
Wilson, Ian A.
7865d500-d638-4a67-ad6d-fefad0ae83bb
Sanders, Rogier W.
d3b67c2c-c725-42e7-b972-50b30be67c74
Hassell, Thomas
ace806e6-2de6-4e21-86e5-0b903c99d40a
Ward, Andrew
0175d681-1283-4b75-a75f-b98609660b3d
Moore, John P.
3c26226c-c036-48db-bbd1-828a86b29697

Dey, Antu K., Cupo, Albert, Ozorowski, Gabriel, Sharma, Vaneet K., Behrens, Anna-Janina, Go, Eden P., Ketas, Thomas J., Yasmeen, Anila, Klasse, Per J., Sayeed, Eddy, Desaire, Heather, Crispin, Max, Wilson, Ian A., Sanders, Rogier W., Hassell, Thomas, Ward, Andrew and Moore, John P. (2018) cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. Biotechnology and Bioengineering, 115 (4), 885–899. (doi:10.1002/bit.26498).

Record type: Article

Abstract

We describe the properties of BG505 SOSIP.664 HIV-1 envelope glycoprotein trimers produced under current Good Manufacturing Practice (cGMP) conditions. These proteins are the first of a new generation of native-like trimers that are the basis for many structure-guided immunogen development programs aimed at devising how to induce broadly neutralizing antibodies (bNAbs) to HIV-1 by vaccination. The successful translation of this prototype demonstrates the feasibility of producing similar immunogens on an appropriate scale and of an acceptable quality for Phase I experimental medicine clinical trials. BG505 SOSIP.664 trimers are extensively glycosylated, contain numerous disulfide bonds and require proteolytic cleavage, all properties that pose a substantial challenge to cGMP production. Our strategy involved creating a stable CHO cell line that was adapted to serum-free culture conditions to produce envelope glycoproteins. The trimers were then purified by chromatographic methods using a 2G12 bNAb affinity column and size-exclusion chromatography. The chosen procedures allowed any adventitious viruses to be cleared from the final product to the required extent of >12 log10. The final cGMP production run yielded 3.52 g (peptidic mass) of fully purified trimers (Drug Substance) from a 200 L bioreactor, a notable yield for such a complex glycoprotein. The purified trimers were fully native-like as judged by negative-stain electron microscopy, and were stable over a multi-month period at room temperature or below and for at least 1 week at 50°C. Their antigenicity, disulfide bond patterns, and glycan composition were consistent with trimers produced on a research laboratory scale. The methods reported here should pave the way for the cGMP production of other native-like Env glycoprotein trimers of various designs and genotypes.

Text
Dey_et_al_2017_Biotechnology_and_Bioengineering_1_1_ - Accepted Manuscript
Download (917kB)
Text
Dey_et_al-2018-Biotechnology_and_Bioengineering (1) - Version of Record
Available under License Creative Commons Attribution.
Download (2MB)
Text
Dey_et_al-2017-Biotechnology_and_Bioengineering (1)(1) Accepted pre-print
Restricted to Repository staff only
Request a copy

More information

Accepted/In Press date: 14 November 2017
e-pub ahead of print date: 11 December 2017
Published date: April 2018

Identifiers

Local EPrints ID: 416347
URI: http://eprints.soton.ac.uk/id/eprint/416347
ISSN: 0006-3592
PURE UUID: fd1adaaa-a41b-4ba9-9e83-f79378c41e32
ORCID for Max Crispin: ORCID iD orcid.org/0000-0002-1072-2694

Catalogue record

Date deposited: 13 Dec 2017 17:30
Last modified: 12 Jul 2024 04:08

Export record

Altmetrics

Contributors

Author: Antu K. Dey
Author: Albert Cupo
Author: Gabriel Ozorowski
Author: Vaneet K. Sharma
Author: Anna-Janina Behrens
Author: Eden P. Go
Author: Thomas J. Ketas
Author: Anila Yasmeen
Author: Per J. Klasse
Author: Eddy Sayeed
Author: Heather Desaire
Author: Max Crispin ORCID iD
Author: Ian A. Wilson
Author: Rogier W. Sanders
Author: Thomas Hassell
Author: Andrew Ward
Author: John P. Moore

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×